title: Tolerance to nicotine in mice lacking alpha7 nicotinic receptors.
abstract: BACKGROUND
  Previous studies have suggested that a knockout of the gene coding for alpha7 nicotinic receptor subunits influences the behaviour of undrugged mice but not the acute effect of nicotine on locomotor activity.
  
  
  OBJECTIVE
  The present studies extend these observations to nicotine tolerance assessed by means of schedule-controlled behaviour.
  
  
  METHODS
  Groups of alpha7-/- and alpha7+/+ mice were trained to press levers under an FR20 schedule of food reinforcement. The acute response rate-depressant effects of nicotine were determined in both genotypes and the mice were then subdivided into groups treated daily with nicotine (1.2 mg/kg/day) or saline. After 39 days of exposure to this regimen, the dose-response curves were re-determined.
  
  
  RESULTS
  Knockout of the alpha7 gene had no consistent effect on the lever-pressing behaviour of undrugged mice and did not influence the acute, dose-related, response rate-depressant effect of nicotine (0.2-1.2 mg/kg). When dose-response curves for nicotine (0.4-2.0 mg/kg) were re-determined after daily dosing with the drug, both wild-type and knockout mice developed similar tolerance to nicotine, as shown by approximately 2.5-fold shifts to the right of the dose-response curves.
  
  
  CONCLUSIONS
  Nicotinic receptors containing the alpha7 subunit do not play a significant role in the regulation of the lever-pressing behaviour studied or in the acute behavioural depressant effect of nicotine and the development of tolerance to that effect. Such results contrast with previous reports suggesting profound impairments in sensitivity to nicotine in nicotinic receptor beta2-/- mice.
authors.affiliation: Section of Behavioural Pharmacology, Institute of Psychiatry P049, King's College London, London, SE5 8AF, UK.
authors.forename: C
authors.initials: C
authors.lastname: Naylor
authors.forename: D
authors.initials: D
authors.lastname: Quarta
authors.forename: C
authors.initials: C
authors.lastname: Fernandes
authors.forename: I P
authors.initials: IP
authors.lastname: Stolerman
mesh_terms: D000818:Animals; D003216:Conditioning, Operant / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance / Q000235:genetics*; D005260:Female; D005838:Genotype; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009538:Nicotine / Q000008:administration & dosage / Q000494:pharmacology*; D011978:Receptors, Nicotinic / Q000235:genetics / Q000502:physiology*; D012055:Reinforcement Schedule; D013997:Time Factors; D064569:alpha7 Nicotinic Acetylcholine Receptor
chemical_list: C579166:Chrna7 protein, mouse; D011978:Receptors, Nicotinic; D064569:alpha7 Nicotinic Acetylcholine Receptor; D009538:Nicotine
references.citation: Neuron. 2000 Aug;27(2):349-57
references.pmid: 10985354
references.citation: Pharmacol Biochem Behav. 1991 Sep;40(1):53-9
references.pmid: 1780345
references.citation: J Pharmacol Exp Ther. 2000 Sep;294(3):1112-9
references.pmid: 10945867
references.citation: Neuropharmacology. 2002 Mar;42(4):530-9
references.pmid: 11955523
references.citation: Psychopharmacologia. 1973 Jun 29;30(4):329-42
references.pmid: 4722204
references.citation: J Pharmacol Exp Ther. 1996 Apr;277(1):454-61
references.pmid: 8613954
references.citation: Psychopharmacologia. 1974 Feb 6;34(4):317-24
references.pmid: 4812657
references.citation: Nicotine Tob Res. 2001 Nov;3(4):361-73
references.pmid: 11694204
references.citation: Neuropharmacology. 2000 Oct;39(13):2840-7
references.pmid: 11044754
references.citation: Psychopharmacology (Berl). 1982;77(4):339-43
references.pmid: 6813894
references.citation: Psychopharmacology (Berl). 1999 Jan;141(3):332-8
references.pmid: 10027516
references.citation: Neuropharmacology. 2003 Mar;44(3):367-73
references.pmid: 12604094
references.citation: J Neurosci. 1997 Dec 1;17(23):9165-71
references.pmid: 9364063
references.citation: Learn Mem. 1998 Sep-Oct;5(4-5):302-16
references.pmid: 10454356
references.citation: Psychopharmacology (Berl). 1997 Feb;129(4):390-7
references.pmid: 9085409
references.citation: Brain Res Bull. 1995;37(4):359-62
references.pmid: 7620908
references.citation: Nicotine Tob Res. 2004 Feb;6(1):145-58
references.pmid: 14982698
references.citation: J Pharmacol Exp Ther. 1981 Mar;216(3):484-91
references.pmid: 7205628
references.citation: J Pharmacol Exp Ther. 1991 Oct;259(1):392-402
references.pmid: 1920127
references.citation: Psychopharmacology (Berl). 2000 May;149(4):388-96
references.pmid: 10867966
references.citation: Nature. 1998 Jan 8;391(6663):173-7
references.pmid: 9428762
references.citation: Neuroreport. 1999 Mar 17;10(4):697-702
references.pmid: 10208533
references.citation: Int J Neuropharmacol. 1967 May;6(3):229-40
references.pmid: 6037527
references.citation: Neuropsychopharmacology. 2004 May;29(5):891-900
references.pmid: 14970827
references.citation: Psychopharmacology (Berl). 1988;96(1):7-14
references.pmid: 3147478
references.citation: Neuropharmacology. 2004 Mar;46(3):363-71
references.pmid: 14975691
references.citation: Psychopharmacology (Berl). 1989;97(3):295-302
references.pmid: 2497478